Laserable and releasable sutures preferable after trabeculectomy

Article

Laser suture lysis or releasable suture techniques can be a preferable alternative to permanent sutures for closing scleral flaps in primary trabeculectomy with mitomycin C (MMC) in uncomplicated glaucoma, according to a study published in the March issue of Journal of Glaucoma.

Laser suture lysis or releasable suture techniques can be a preferable alternative to permanent sutures for closing scleral flaps in primary trabeculectomy with mitomycin C (MMC) in uncomplicated glaucoma, according to a study published in the March issue of Journal of Glaucoma.

The study, conducted by Dr Umit Aykan and colleagues, compared the efficacy and complication rates of laser suture lysis (LSL) or releasable suture techniques after trabeculectomy. The study analysed 48 eyes of 43 patients with uncomplicated glaucoma who were recruited for primary trabeculectomy with MMC. The patients were divided into two groups of 27 and 21 eyes that were randomly assigned to a standard surgery and releasable suture groups respectively. A target intraocular pressure (IOP) was determined on the basis of the severity of the glaucoma and was called a complete success, qualified success or failure.

Group 1 recorded a mean change in IOP after LSL of 7.31±1.98 mmHg, 6.1±1.1 mmHg and 3.9±1.5 mmHg when sutures were lysed on the first, second and third months, respectively. In group 2, the mean change in IOP after releasable suture removal was 8.20±2.74 mmHg, 5.12±1.65 mmHg and 4.4±1.0 mmHg, respectively. After six months, the success rates were 92% and 90% for LSL and releasable suture groups, respectively.

The study concluded that there is an effective IOP reduction in eyes that had suture release both in the early and late postoperative periods after LSL and suture release. Both the laserable and releasable suture techniques can therefore be preferred to permanent sutures for closing scleral flaps in primary trabeculectomy with MMC in uncomplicated glaucoma.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.